Organisation paid for research Program year 2025 Source: CMS Open Payments

Omega Research Debary LLC

Neither a doctor nor a teaching hospital

Research payments

$2,335,378

377 payments

Through program year 2025, Omega Research Debary LLC is reported as receiving $2,335,378 in research payments, across 377 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $515,549 62
2024 Research $972,492 116
2023 Research $477,229 79
2022 Research $180,451 46
2021 Research $40,445 15
2020 Research $41,209 16
2019 Research $108,003 43

Breakdown

Who paid Research payments · program years 2019–2025
  1. Sanofi US Services Inc. $1,017,096 141 payments
  2. AbbVie, Inc. $541,796 62 payments
  3. GlaxoSmithKline, LLC. $290,200 50 payments
  4. Janssen Research & Development, LLC $194,079 27 payments
  5. AstraZeneca Pharmaceuticals LP $120,404 7 payments
  6. Genzyme Corporation $52,324 12 payments
  7. Chiesi USA, Inc. $40,527 9 payments
  8. Kadmon Corporation LLC $23,865 4 payments
  9. Kiniksa Pharmaceuticals International, plc $23,356 10 payments
  10. Pfizer Inc. $20,755 51 payments
Studies the money was for Research payments · program years 2019–2025
  1. Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) $638,188 71 payments
  2. Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) $322,184 23 payments
  3. A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Para $158,400 30 payments
  4. A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies $127,538 18 payments
  5. A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154 $102,815 19 payments
  6. A Phase IV, 12-Week, Randomised, Double-Blind, Triple Dummy Study to C $83,200 9 payments
  7. A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Adult Patients With Primary Sjogren's Syndrome (pSjS) $71,251 13 payments
  8. A Phase 2a Multi Center Randomized Double blind Study Evaluating the Efficacy and Safety of Subcutaneously Administered Guselkumab and Golimumab Combination Therapy in Participants with Active Psoriatic Arthritis $62,660 14 payments
  9. Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study $58,696 19 payments
  10. A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis $54,800 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record